These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22596349)

  • 21. The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
    Madison DL; Stauffer D; Lundblad JR
    DNA Repair (Amst); 2011 Oct; 10(10):1003-13. PubMed ID: 21840268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.
    Dent P; Tang Y; Yacoub A; Dai Y; Fisher PB; Grant S
    Mol Interv; 2011 Apr; 11(2):133-40. PubMed ID: 21540473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
    Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
    Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
    Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
    DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
    Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
    Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCL2 suppresses PARP1 function and nonapoptotic cell death.
    Dutta C; Day T; Kopp N; van Bodegom D; Davids MS; Ryan J; Bird L; Kommajosyula N; Weigert O; Yoda A; Fung H; Brown JR; Shapiro GI; Letai A; Weinstock DM
    Cancer Res; 2012 Aug; 72(16):4193-203. PubMed ID: 22689920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
    Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
    Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.
    Guo N; Li MZ; Wang LM; Chen HD; Song SS; Miao ZH; He JX
    Cancer Biol Ther; 2022 Dec; 23(1):69-82. PubMed ID: 35000525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological and clinical significance of PARP1 protein expression in breast cancer.
    Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
    Brenner JC; Ateeq B; Li Y; Yocum AK; Cao Q; Asangani IA; Patel S; Wang X; Liang H; Yu J; Palanisamy N; Siddiqui J; Yan W; Cao X; Mehra R; Sabolch A; Basrur V; Lonigro RJ; Yang J; Tomlins SA; Maher CA; Elenitoba-Johnson KS; Hussain M; Navone NM; Pienta KJ; Varambally S; Feng FY; Chinnaiyan AM
    Cancer Cell; 2011 May; 19(5):664-78. PubMed ID: 21575865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
    Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
    Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
    Bieche I; Pennaneach V; Driouch K; Vacher S; Zaremba T; Susini A; Lidereau R; Hall J
    Int J Cancer; 2013 Dec; 133(12):2791-800. PubMed ID: 23736962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab-Resistant HER2
    Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
    Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.